Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical isolates from Switzerland.

Publikation

Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical isolates from Switzerland.

Wissenschaftlicher Artikel/Review - 25.04.2023

Babouee Flury Baharak, Bösch Anja, Gisler Valentin, Egli Adrian, Seiffert Salome N, Nolte Oliver, Findlay Jacqueline

Zitation

Babouee Flury B, Bösch A, Gisler V, Egli A, Seiffert S, Nolte O, Findlay J. Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical isolates from Switzerland. Front Cell Infect Microbiol 2023; 13:1098944.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Front Cell Infect Microbiol 2023; 13

Veröffentlichungsdatum

25.04.2023

eISSN (Online)

2235-2988

Seiten

1098944

Kurzbeschreibung/Zielsetzung

Increasing reports of multidrug resistance (MDR) in clinical have led to a necessity for new antimicrobials. Ceftazidime-avibactam (CZA) is indicated for use against MDR across a broad range of infection types and particularly those that are carbapenem resistant. This study sought to determine the molecular mechanisms of CZA and imipenem (IPM)-resistance in clinical isolates obtained from Swiss hospitals.